Home  |  Contact

UniProtKB/Swiss-Prot P07686: Variant p.Pro504Ser

Beta-hexosaminidase subunit beta
Gene: HEXB
Variant information

Variant position:  504
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Proline (P) to Serine (S) at position 504 (P504S, p.Pro504Ser).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and hydrophobic (P) to small size and polar (S)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In GM2G2; decreases the isozyme A transport out of the endoplasmic reticulum. Lowers its heat stability. Affects the ability of isozyme A to hydrolyze GM2 ganglioside.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  504
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  556
The length of the canonical sequence.

Location on the sequence:   GEACLWGEYVDATNLTPRLW  P RASAVGERLWSSKDVRDMDD
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         GEACLWGEYVDATNLTPRLWPRASAVGERLWSSKDVRDMDD

Mouse                         GEACLWGEFVDATNLTPRLWPRASAVGERLWSPKTVTDLEN

Rat                           GEACLWGEYVDATNLIPRLWPRASAVGERLWSPRIITNLEN

Pig                           GEACLWGEYVDATNLTPRLWPRASAVGERLWSHKDVRDIHD

Cat                           GEACLWGEFVDATNLTPRLWPRASAVGERLWSPEDITSVGN

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 122 – 556 Beta-hexosaminidase subunit beta
Chain 315 – 556 Beta-hexosaminidase subunit beta chain A
Site 497 – 497 Not glycosylated


Literature citations

A Pro504 --> Ser substitution in the beta-subunit of beta-hexosaminidase A inhibits alpha-subunit hydrolysis of GM2 ganglioside, resulting in chronic Sandhoff disease.
Hou Y.; McInnes B.; Hinek A.; Karpati G.; Mahuran D.;
J. Biol. Chem. 273:21386-21392(1998)
Cited for: VARIANT GM2G2 SER-504; CATALYTIC ACTIVITY; FUNCTION; CHARACTERIZATION OF VARIANT GM2G2 SER-504; SUBCELLULAR LOCATION;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.